Nasal whooping cough vaccine gets a boost: higher dose tested in adults
NCT ID NCT02453048
First seen Mar 05, 2026 · Last updated Jun 16, 2026 · Updated 15 times
Summary
This study tested a higher dose of a new nasal vaccine (BPZE1) for whooping cough in 54 healthy adults aged 18-32. The goal was to see if the higher dose is safe and helps the vaccine take hold in the nose to trigger protection. Researchers monitored side effects and checked if the vaccine colonized the nose over 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WHOOPING COUGH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karolinska University Hospital
Huddinge, Stockholm County, 141 86, Sweden
Conditions
Explore the condition pages connected to this study.